# 510(k) Summary

This summary of 510(k) safety and effectiveness information is supplied in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510 (k) number is K100101

Date: June 10, 2010

# Submitted by:

Wallac Oy, Division of PerkinElmer Inc. Mustionkatu 6   
20750 Turku, Finland

Contact Person: Primary:

Kay A. Taylor Tele: 317 418-1735 Fax: 317 536-3064

Secondary:

Kati Suonpaa Tele: (01 1) +358 2 2678 402 Fax: (011) $+ 3 5 8 - 2 { \cdot } 2 6 7 8 3 5 7$

# Trade Name:

GSP Neonatal GALT kit (3303-001U)

Common Name: Regulation:

GSP Neonatal GALT kit (21 CFR 862.1315)

Classification Name: Product Code:

Galactose-1-phosphate uridyl transferase test system (KQP)

Predicate device:

Neonatal GALT (formerly Isolab Galactose-1-Phosphate Uridyl Tranferase test) (K950803)

# Device Description:

The GSPTM Neonatal GALT assay is an adaptation of the quantitative enzymatic assay of Beutler and Baluda. The fluorescence is measured with the GSP Instrument using an excitation wavelength of $3 5 5 ~ \mathrm { { n m } }$ and an emission wavelength of $4 6 0 ~ \mathrm { n m }$ . The GSP Neonatal GALT assay uses prompt fluorescence technology.

# Intended Use:

This kit (GSP'TM Neonatal GALT) is intended for the quantitative determination of galactose-1-phosphate uridyl transferase (GALT) activity in blood specimens dried on filter paper as an aid in screening newborns for classical galactosemia caused by GALT deficiency using the GSPTM instrument.

# Device Comparison:

<table><tr><td colspan="3" rowspan="1">Comparison of the GSP Neonatal GALT device with its predicate.</td></tr><tr><td colspan="3" rowspan="1">GSP Neonatal GALT Test System</td></tr><tr><td colspan="1" rowspan="1">Characteristics</td><td colspan="1" rowspan="1">Proposed Device</td><td colspan="1" rowspan="1">Neonatal GALT (K950803)</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications forUse</td><td colspan="1" rowspan="1">This kit (GSP Neonatal GALT) isintended for the quantitativedetermination of galactose-1-phosphate uridyl transferase(GALT) activity in bloodspecimens dried on filter paper asan aid in screening newborns forclassical galactosemia caused byGALT deficiency using theGSPTM instrument.The GSP instrument and GSPchemistries are for professionaluse only.</td><td colspan="1" rowspan="1">This kit (Neonatal GALT) isintended for the semi-quantitativedetermination of galactose-1-phosphate uridyl transferase(GALT) activity in blood specimensdried on filter paper as an aid inscreening newborns for classicalgalactosemia caused by GALTdeficiency</td></tr><tr><td colspan="1" rowspan="1">Intended User</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Adequately trained laboratorypersonnel performing newbornscreening</td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatform</td><td colspan="1" rowspan="1">GSP instrument</td><td colspan="1" rowspan="1">1420 Victor D series fluorometer</td></tr><tr><td colspan="1" rowspan="1">Test Mode</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Batch mode</td></tr><tr><td colspan="1" rowspan="1">DetectionTechnology</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Prompt fluorescence</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Dried blood spots.</td></tr><tr><td colspan="1" rowspan="1">Plate Capacity</td><td colspan="1" rowspan="1">26 plates</td><td colspan="1" rowspan="1">1 plate</td></tr><tr><td colspan="1" rowspan="1">Reagents</td><td colspan="1" rowspan="1">Individually bar-coded reagents</td><td colspan="1" rowspan="1">No bar-coded reagents</td></tr><tr><td colspan="1" rowspan="1">User Interface</td><td colspan="1" rowspan="1">GSP software -MicroSoftWindows Vista embedded - touchscreen</td><td colspan="1" rowspan="1">Wallac 1420 D software running onMicroSoft Windows XPProfessional</td></tr><tr><td colspan="1" rowspan="1">InstrumentComponents</td><td colspan="1" rowspan="1">Instrument (consists of platemanipulator and modules).External PCBarcode reader.</td><td colspan="1" rowspan="1">InstrumentPrinterComputer</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Six levels of GALT calibrators</td></tr><tr><td colspan="1" rowspan="1">Source</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Sheep blood with GALT,phosphoglucomutase, glucose-6-phosphate dehydrogenase anddithiothreitol with ProClin 300 aspreservative.</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Filter paper cassettes(Whatman no.903)</td><td colspan="1" rowspan="1">Filter paper sheets(Whatman no. 903)</td></tr><tr><td colspan="1" rowspan="1">Concentrations</td><td colspan="1" rowspan="1">A 1 U/dLB 3 U/dLC 6 U/dLD 9 U/dLE 15 U/dLF 25 U/dL</td><td colspan="1" rowspan="1">A 1.8 U/g HbB 5 U/g HbC 8 U/g HbD 11 U/g HbE 14 U/g HbF 18 U/g Hb</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Two levels of GALT controls</td></tr><tr><td colspan="1" rowspan="1">Source</td><td colspan="1" rowspan="1">Human and sheep blood withProClin 300 as preservative</td><td colspan="1" rowspan="1">Sheep blood with GALT,phosphoglucomutase, glucose-6-phosphate dehydrogenase anddithiothreitol with ProClin 300 aspreservative.</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Filter paper cassettes(Whatman no.903)</td><td colspan="1" rowspan="1">Filter paper sheets(Whatman no. 903)</td></tr><tr><td colspan="1" rowspan="1">Concentrations</td><td colspan="1" rowspan="1">Approx. values:Low 4 U/dLHigh 13 U/dL</td><td colspan="1" rowspan="1">Approx. values:Normal 12.7 U/g HbAbnormal 2.1 U/g Hb</td></tr><tr><td colspan="1" rowspan="1">Substrate ReagentIngredients</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Contains beta-nicotinamide adeninedinucleotide phosphate,uridine 5'-diphosphoglucose, galactose-1-phosphate, and dithiothreitol</td></tr><tr><td colspan="1" rowspan="1">ReconstitutionBuffer</td><td colspan="1" rowspan="1">Ready-for-use buffer containsmagnesium sulfate,ethylenediaminetetraacetic acid,tris aminomethane, Triton X-100,and ProClin 300 as preservative.</td><td colspan="1" rowspan="1">Ready-for-use buffer containsmagnesium sulphate,ethylenediaminetetraacetic acid, triaminomethane, and ProClin 300 aspreservative.</td></tr><tr><td colspan="1" rowspan="1">MicroPlates</td><td colspan="1" rowspan="1">Clear uncoated, sold separately</td><td colspan="1" rowspan="1">Black uncoated</td></tr><tr><td colspan="1" rowspan="1">Detection</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Defined by analyte specific protocol</td></tr><tr><td colspan="1" rowspan="1">Calculation</td><td colspan="1" rowspan="1">GSP Workstation software,X-axis LIN, Y-axis LIN; fittingalgorithm linear regression</td><td colspan="1" rowspan="1">The system incorporates programsfor data reduction, and the resultsobtained as printouts of calibrationcurves, unknown activities etc.</td></tr><tr><td colspan="1" rowspan="1">Incubation Detail</td><td colspan="1" rowspan="1">20 min + 2 hours, 37°C</td><td colspan="1" rowspan="1">3 hours, 37°C and 60min, RT</td></tr><tr><td colspan="1" rowspan="1">Testing IntegrityControls</td><td colspan="1" rowspan="1">Floating Disk Control - detectsfloating sample disks in the wells beforemeasuring GALT activityElution Control - detects missingsample disks in the wells aftermeasuring GALT activity</td><td colspan="1" rowspan="1">Not available</td></tr></table>

# Performance Characteristics

Precision:

Precision was determined in accordance with NCCLS (CLSI) document EP5-A2.

The variation of the GSP Neonatal GALT assay was determined using dried blood spot samples and controls, 3 kit lots, and 3 GSP instruments. The study was performed over 25 days in 27 runs each consisting of 2 plates with 4 replicates per sample. The analysis of variance approach was used to calculate the following:

Precision data using a full calibration curve on each plate:   

<table><tr><td rowspan=1 colspan=9>RESULTS</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>n</td><td rowspan=2 colspan=1>MeanGALTactivity(U/dL)</td><td rowspan=1 colspan=2>Within runvariation</td><td rowspan=1 colspan=2>Within lotvariation</td><td rowspan=1 colspan=2>Total variation</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>209*</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>14.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>15.9</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>13.1</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>206*</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>8.6</td></tr><tr><td rowspan=1 colspan=1>S4</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>9.2</td></tr><tr><td rowspan=1 colspan=1>S5</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>7.6</td></tr><tr><td rowspan=1 colspan=1>S6</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>13.1</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>9.1</td></tr><tr><td rowspan=1 colspan=1>S7</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>18.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>S8</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>22.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.2</td></tr></table>

\* Some results have been excluded because of technical errors.

Precision data using one calibration curve valid for $^ { 2 4 \mathrm { ~ h ~ } }$ .   

<table><tr><td rowspan=1 colspan=9>RESULTS</td></tr><tr><td rowspan=2 colspan=1>Sample.</td><td rowspan=2 colspan=1>n</td><td rowspan=2 colspan=1>MeanGALTactivity(U/dL)</td><td rowspan=1 colspan=2>Within runvariation</td><td rowspan=1 colspan=2>Within lotvariation</td><td rowspan=1 colspan=2>Total variation</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>209*</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>14.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>15.7</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>12.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>13.6</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>206*</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>9.0</td></tr><tr><td rowspan=1 colspan=1>S4</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>9.8</td></tr><tr><td rowspan=1 colspan=1>SS</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>S6</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>9.5</td></tr><tr><td rowspan=1 colspan=1>S7</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>18.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>S8</td><td rowspan=1 colspan=1>216</td><td rowspan=1 colspan=1>22.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>5.8</td></tr></table>

\* Some results have been excluded because of technical errors.

Linearity:

Linearity was determined in accordance with NCCLS document EP6-A.

For GALT activities over $4 \ : \mathrm { U / d L }$ , the maximum observed difference $( \% )$ between the linear and ${ \mathfrak { Z } } ^ { \mathsf { r d } }$ order regression models is $- 2 . 6 \%$ . For activities $\leq 4 ~ \mathrm { U } / \mathrm { d L }$ , the maximum observed absolute difference between the models is $0 . 0 7 \mathrm { U } / \mathrm { d L }$ .

For GSP Neonatal GALT, the method has been demonstrated to be linear throughout the measuring range, from extends from $2 . 5 \mathrm { U } / \mathrm { d L }$ to $2 5 \ \mathrm { U } / \mathrm { d L }$ .

# Detection Limit:

The limits of blank, detection and quantitation were determined in accordance with NCCL document EP17-A.

The Limit of Blank (LoB) for GSP Neonatal GALT kit is $1 . 6 \ : \mathrm { U / d L }$ , defined as the $9 5 ^ { 1 \mathrm { { h } } }$ percentile of a distribution of blank (GALT deficient) samples $( \mathrm { n } { = } 8 3 )$ The Limit of Detection (LoD) is $2 . 5 \ \mathrm { U } / \mathrm { d } \mathrm { L }$ based on 351 determinations of five low level samples. The Limit of Quantitation (LoQ) is $2 . 5 \ : \mathrm { U } / \mathrm { d } \mathrm { L }$ , defined as the lowest activity with a total CV equal or less than $20 \%$ $( \mathfrak { n } ^ { = 2 0 9 }$

# Analytical Specificity:

The GSP Neonatal GALT kit was evaluated for interference in accordance with CLSI document EP7-A2.

Whole blood with three different GALT activities (approximately 3, 6 and $1 2 \ : \mathrm { U } / \mathrm { d } \mathrm { L } )$ were enriched above the endogenous levels with possible interfering substances as presented below.

Icteric (unconjugated bilirubin $( \leq 4 0 ~ \mathrm { m g / d L }$ blood), conjugated bilirubin $( \leq 4 0 ~ \mathrm { m g / d L }$ E blood)) and lipemic (Intralipid $\leq 1 0 0 0 ~ \mathrm { m g / d L }$ blood) samples did not interfere with the assay. Ascorbic acid $( \leq 3 \ \mathrm { m g / d L }$ blood) and galactose $\mathrm { ( \leq 5 0 \ m g / d L }$ blood) did not interfere with the assay at tested concentrations.

Glutathione did not interfere up to concentration of 18.8, 37.5 and $5 6 . 3 ~ \mathrm { m g / d L }$ blood at sample GALT activities of 3, 6 and $1 2 \mathrm { U } / \mathrm { d L }$ , respectively. Glutathione concentrations above these levels caused a decrease of up to $6 3 \%$ in GALT activity.

Galactose-1-phosphate (GAL-1-P) had no effect on the low GALT activity sample (3 $\mathrm { U } / \mathrm { d L } )$ , while a GAL-1-P concentration of $1 2 . 5 ~ \mathrm { m g / d L }$ blood interfered with the result of the samples with GALT activities 6 and $1 2 \ \mathrm { U / d L }$ . The measured GALT result decreased up to $3 7 \%$ .

Total protein (HSA) had no effect on the high $( 1 2 \mathrm { U } / \mathrm { d L } )$ activity sample. HSA did not interfere up to added concentration of $3 0 0 0 ~ \mathrm { { m g / d L } }$ blood, which is approximately two times higher than the normal endogenous concentration of normal neonates, at sample GALT activities 3 and 6 U/dL. Added HSA concentrations above this level caused an increase up to $30 \%$ in GALT activity.

The effect of hematocrit was tested by adjusting the amount of red blood cells with plasma on three whole blood samples with different GALT activities (approximately ${ < } 1$ , 6, and $1 5 \mathrm { U } / \mathrm { d L }$ , and testing the blood samples for GALT activity according to CLSI document EP7-A2. The results are shown below.

# Effect of hematocrit

<table><tr><td rowspan=2 colspan=1>Hematocrit %(approximatevalue)</td><td rowspan=1 colspan=2>Sample 1   I</td><td rowspan=1 colspan=2>Sample 2</td><td rowspan=1 colspan=2>Sample 3</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>U/dL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>U/dL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>U/dL</td></tr><tr><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>13.2</td></tr><tr><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>14.9</td></tr><tr><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15.4</td></tr><tr><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>15.6</td></tr><tr><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>15.2</td></tr></table>

Samples with low GALT activity might get slightly elevated or lowered results from the GSP Neonatal GALT assay due to differences in the hematocrit level. GALT activity is in the red blood cells and hence the GALT activity varies based on hematocrit level. However, hemoglobin is known to absorb part of the excitation and emission light. In samples with normal GALT activity the change in hematocrit is compensated with the hemoglobin effect. In samples with low GALT activity there is not enough GALT activity to overcome the quenching effect of hemoglobin and thus the samples with low GALT activity and low hematocrit may result in elevated results and samples with low GALT activity and high hematocrit may result in lower results.

The differences in hematocrit level have no effect on the screening classification of samples with no GALT activity (classical galactosemia).

# Comparison Studies:

The 3303-001U GSP Neonatal GALT kit was compared to the NG-1100/4100 Neonatal GALT kit in a routine screening laboratory by measuring the GALT activity in a total of 2205 infants. The specimens were routine $( \mathsf { n } = 2 1 4 6 )$ and retrospective low GALT activity $\mathrm { ( n } = 3 3 \mathrm { ) }$ ) screening specimens. A comparison of the routine screening samples is provided in the table below.

<table><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>0.5thpercentile</td><td rowspan=1 colspan=1>1.0stpercentile</td><td rowspan=1 colspan=1>1.5thpercentile</td></tr><tr><td rowspan=1 colspan=1>GSP3303-001U(U/dL)</td><td rowspan=1 colspan=1>2146</td><td rowspan=1 colspan=1>2.5-25*</td><td rowspan=1 colspan=1>15.5</td><td rowspan=1 colspan=1>15.6</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>7.5</td></tr><tr><td rowspan=1 colspan=1>NG-1100/4100(U/g Hb)</td><td rowspan=1 colspan=1>2146</td><td rowspan=1 colspan=1>3.0-18</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>6.1</td></tr></table>

\* Samples that resulted in values below 2.5 U/dL were reported as $\because < 2 . 5 \ : \mathrm { U } / \mathrm { d L } ^ { \prime }$ and samples that resulted in values above $2 5 \mathrm { U } / \mathrm { d L }$ were reported as $\because { 2 5 } \mathrm { U } / \mathrm { d } \mathrm { L } ^ { \ast }$

# Screening Performance

Cut-off values based on the $0 . 5 ^ { \mathrm { t h } } , 1 . 0 ^ { \mathrm { s t } }$ , and $1 . 5 ^ { \mathrm { t h } }$ percentiles were used for both methods.

Samples that resulted in values below $2 . 5 \ \mathrm { ~ U } / \mathrm { d } \mathrm { L }$ were reported $\mathbb { s } ^ { \mathrm { \infty } } < 2 . 5 \mathrm { ~ U / d L ^ { \mathrm { \infty } } ~ }$ and considered screen positive for classical galactosemia. Samples that resulted in values above $2 5 ~ \mathrm { U } / \mathrm { d } \mathrm { L }$ were reported as" ${ > } 2 5$ U/dL" and considered screen negative for classical galactosemia.

Please note that the cut-off values used in this section only apply to this study. If the measured median GALT activity of routine samples is lower than the values given in this section, a higher percentile should be used to determine the cut-off (see sections "SPECIMEN COLLECTION AND HANDLING" and "EXPECTED VALUES AND INTERPRETATION OF RESULTS").

Screening performance using the $0 . 5 ^ { 1 1 1 }$ percentile   

<table><tr><td rowspan=1 colspan=1>NeonatalGALT kit</td><td rowspan=1 colspan=3>NG-1100/4100</td></tr><tr><td rowspan=1 colspan=1>GSP 3303-001U</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>39*</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2132</td><td rowspan=1 colspan=1>2135</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>2137</td><td rowspan=1 colspan=1>2179</td></tr></table>

\* Includes all 33 retrospective low GALT activity screening specimens

Overall percent agreement $= ( 3 9 + 2 1 3 2 ) / ( 2 1 7 9 ) ^ { \ast } 1 0 0 \% = 9 9 . 6 \%$ $\operatorname { C I } 9 9 . 3 \% 9 9 . 9 \% )$ Positive percent agreement $= ( 3 9 / 4 2 ) ^ { \ast } 1 0 0 \% = 9 2 . 9 \%$ $\operatorname { C I } 8 3 . 9 \% - 1 0 0 \% )$ Negative percent agreement $= ( 2 1 3 2 / 2 1 3 7 ) ^ { \ast } 1 0 0 \% = 9 9 . 8 \%$ $\mathrm { C I } 9 9 . 5 \% - 1 0 0 \% )$ EMP

Screening performance using the $1 . 0 ^ { \mathsf { s t } }$ percentile.   

<table><tr><td rowspan=1 colspan=1>NeonatalGALT kit</td><td rowspan=1 colspan=3>NG-1100/4100</td></tr><tr><td rowspan=1 colspan=1>GSP 3303-001U</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>45*</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>2118</td><td rowspan=1 colspan=1>2126</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>2126</td><td rowspan=1 colspan=1>2179</td></tr></table>

\* Includes all 33 retrospective low GALT activity screening specimens

Overall percent agreement $: = ( 4 5 + 2 1 1 8 ) / ( 2 1 7 9 ) ^ { \ast } 1 0 0 \% = 9 9 . 3 \%$ $\operatorname { C I } 9 8 . 9 \% - 9 9 . 7 \% )$ EPY Positive percent agreement $= ( 4 5 / 5 3 ) * 1 0 0 \% = 8 4 . 9 \%$ (CI 74.3%95.5%) Negative percent agreement $, = ( 2 1 1 8 / 2 1 2 6 ) ^ { \ast } 1 0 0 \% = 9 9 . 6 \%$ $( \mathrm { C I } 9 9 . 3 \% - 9 9 . 9 \% )$

Screening performance using the $1 . 5 ^ { \mathrm { t h } }$ percentile.   

<table><tr><td rowspan=1 colspan=1>NeonatalGALT kit</td><td rowspan=1 colspan=3>NG-1100/4100</td></tr><tr><td rowspan=1 colspan=1>GSP 3303-001U</td><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Test Positive</td><td rowspan=1 colspan=1>51*</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>Test Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>2104</td><td rowspan=1 colspan=1>2114</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>2118</td><td rowspan=1 colspan=1>2179</td></tr></table>

\* Includes all 33 retrospective low GALT activity screening specimens

Overall percent agreement $= ( 5 1 + 2 1 0 4 ) / ( 2 1 7 9 ) ^ { * } 1 0 0 \% = 9 8 . 9 \%$ $( \mathrm { C I } 9 8 . 4 \% - 9 9 . 4 \% )$ EMPY Positive percent agreement $= ( 5 1 / 6 1 ) ^ { * } 1 0 0 \% = 8 3 . 6 \%$ $( \mathrm { C I } 7 3 . 5 \% - 9 3 . 7 \% )$ Negative percent agreement $: = ( 2 1 0 4 / 2 1 1 8 ) ^ { \ast } 1 0 0 \% = 9 9 . 3 \%$ $\mathrm { ( C I ~ 9 9 . 0 \% - 9 9 . 7 \% ) }$ E

PerkinElmer, Inc.   
c/o Ms. Kay A. Taylor   
Director, Regulatory and Clinical Affairs 8275 Carloway Road   
Indianapolis, IN 46236

Re: k100101 Trade/Device Name: GSP Neonatal GALT kit Regulation Number: 21 CFR $\ S 8 6 2 . 1 3 1 5$ Regulation Name: Galactose-1-phosphate uridyl transferase test system Regulatory Class: Class ⅡI Product Code: KQP Dated: April 28, 2010 Received: April 30, 2010

Dear Ms. Taylor:

We have reviewed your Section 510(k) premarket.notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate'devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class Ⅱ (Special Controls) or classII (PMA), it may be subject to such.additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical devicerelated adverse events)(21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/36a198df82e0706c4dc5268309a473dffedcbb615afffaa9eebbe822ca4da0f5.jpg)

Courtny C. Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Form

510(k) Number (if known): K100101

Device Name: GSP Neonatal GALT

Indications for Use:

The GSP Neonatal GALT kit is intended for the quantitative determination of galactose-1-phosphate uridyl transferase (GALT) activity in blood specimens dried on filter paper as an aid in screening newborns for classical galactosemia caused by GALT deficiency using the GSprM instrument.

# (PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/bc5fc620d4640a2f40293c088e42794bbb5e56e1a1ebc6752c62608f015c6b55.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety